Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age



Status:Recruiting
Conditions:Food Studies
Therapuetic Areas:Pharmacology / Toxicology
Healthy:No
Age Range:2 - 16
Updated:4/17/2018
Start Date:March 30, 2018
End Date:March 2021
Contact:John F Stover, MD
Email:john.stover@fresenius-kabi.com
Phone:+49 6172 686

Use our guide to learn which trials are right for you!

Prospective, Randomized, Open-Label, Parallel-Group, Active-Controlled, Multicenter Study to Assess Safe and Effective Doses of Kabiven® in Pediatric Patients 2 to 16 Years of Age

Demonstrate the safety and efficacy of Kabiven compared to standard parenteral nutrition (PN)
administered via central vein in pediatric patients (2 to 16 years of age) requiring PN to
meet nutritional needs.


Inclusion Criteria:

- Male or female patients 2 to 16 years of age

- Patients who require at least 80% of their caloric intake as PN at study start, and in
whom an indication for PN is expected for at least 5 days

- Patients who require a central venous line to receive PN or already have a central
venous line in place for other reasons

- Written informed consent from legal representative(s)

Exclusion Criteria:

- Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn
products, or to any of the active substances or excipients

- Severe hyperlipidemia or severe disorders of lipid metabolism characterized by
hypertriglyceridemia (serum triglyceride concentration >1,000 g/dL).

- Inborn errors of amino acid metabolism

- Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency,
myocardial infarction, acidosis and hemodynamic instability requiring significant
vasopressor support)

- Hemophagocytic syndrome.

- PN in the last 7 days prior to study enrollment.

- Need for chronic PN before study start

- Liver enzymes (either AST, ALT, GGPT), or direct bilirubin exceeding 2 x upper limit
of normal range

- Pathologically altered level of any serum electrolyte (sodium, potassium, magnesium,
calcium, chloride, phosphate) unless corrected prior to the start of study treatment

- Pathologically altered blood pH, or oxygen saturation, or carbon dioxide unless
corrected prior to the start of study treatment

- Pregnancy or lactation

- Participation in another clinical study
We found this trial at
2
sites
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2401 Gillham Rd
Kansas City, Missouri 64108
(816) 234-3000
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials